Skip to main content
SpringerLink
Log in

Nephrotic syndrome

Rituximab in childhood steroid-dependent nephrotic syndrome

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Ravani et al. report that rituximab is a safe and effective steroid-sparing and calcineurin-inhibitor-sparing agent in 46 children with idiopathic nephrotic syndrome over a median follow-up of 3 years. What is the risk-to-benefit profile of rituximab compared to that of the other available drugs for treating this disease?

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ravani, P. et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. http://dx.doi.org/10.1038/ki.2013.211.

  2. Sinha, A. & Bagga, A. Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat. Rev. Nephrol. 9, 154–169 (2013).

    Article  CAS  Google Scholar 

  3. Sfikakis, P. P. et al. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123, 66–73 (2007).

    Article  CAS  Google Scholar 

  4. Fornoni, A. et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci. Transl. Med. 3, 85ra46 (2011).

    Article  Google Scholar 

  5. Lombel, R. M., Gipson, D. S. & Hodson, E. M. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr. Nephrol. 28, 415–426 (2013).

    Article  Google Scholar 

  6. Ito, S. et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 26, 1823–1828 (2011).

    Article  Google Scholar 

  7. Fujinaga, S. et al. Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. Eur. J. Pediatr. 172, 513–518 (2013).

    Article  CAS  Google Scholar 

  8. Delbe-Bertin, L., Aoun, B., Tudorache, E., Lapillone, H. & Ulinski, T. Does rituximab induce hypogammaglobulinemia in patients with pediatric idiopathic nephrotic syndrome? Pediatr. Nephrol. 28, 447–451 (2013).

    Article  Google Scholar 

  9. Chaumais, M. C. et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr. Nephrol. 24, 1753–1755 (2009).

    Article  Google Scholar 

  10. Sellier-Leclerc, A. L., Belli, E., Guérin, V., Dorfmüller, P. & Deschênes, G. Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr. Nephrol. http://dx.doi.org/10.1007/s00467-013-2485-9.

Download references

Author information

Authors and Affiliations

  1. Université Paris Descartes, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015, Paris, France

    Olivia Boyer & Patrick Niaudet

Authors
  1. Olivia Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick Niaudet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Niaudet.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyer, O., Niaudet, P. Rituximab in childhood steroid-dependent nephrotic syndrome. Nat Rev Nephrol 9, 562–563 (2013). https://doi.org/10.1038/nrneph.2013.153

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2013.153

  • Springer Nature Limited

This article is cited by

Search

Navigation